



**ISPOR 7th Asia-Pacific
Conference**

3-6 September, 2016
Suntec Singapore Convention &
Exhibition Center
Singapore



Pharmacoeconomics and Outcomes Research in Asia-Pacific: Challenges, Opportunities, and Future Direction

Tuesday Research Poster Presentations

Poster Display Hours – 8:30 AM - 3:00 PM
Poster Author Discussion Hour – 2:00 PM - 3:00 PM

POSTER PRESENTATIONS:

PCN: CANCER
PDB: DIABETES/ENDOCRINE DISORDERS
PIH: INDIVIDUAL'S HEALTH
PIN: INFECTION
PMS: MUSCULAR-SKELETAL DISORDERS

ROWS A-F
ROWS G-K
ROWS K-N
ROWS N-R
ROWS R-T

Research Poster Presentations

Acceptance Code	PDF Page #	Topic – Subtopic
PCN1-PCN11	194	Cancer - Clinical Outcomes Studies
PCN12-PCN37	198	Cancer - Cost Studies
PCN38-PCN47	209	Cancer - Patient-Reported Outcomes & Patient Preference Studies
PCN48-PCN63	213	Cancer - Health Care Use & Policy Studies
PDB1-PDB13	220	Diabetes/Endocrine Disorders - Clinical Outcomes Studies
PDB14-PDB25	225	Diabetes/Endocrine Disorders - Cost Studies
PDM26-PDB39	230	Diabetes/Endocrine Disorders - Patient-Reported Outcomes & Patient Preference Studies
PDB40-PDB49	235	Diabetes/Endocrine Disorders - Health Care Use & Policy Studies
PIH1-PIH4	240	Individual's Health - Clinical Outcomes Studies
PIH5-PIH9	242	Individual's Health - Cost Studies
PIH10-PIH15	244	Individual's Health - Patient-Reported Outcomes & Patient Preference Studies
PIH16-PIH28	246	Individual's Health - Health Care Use & Policy Studies
PIN1-PIN9	252	Infection - Clinical Outcomes Studies
PIN10-PIN28	255	Infection - Cost Studies
PIN29-PIN33	263	Infection - Patient-Reported Outcomes & Patient Preference Studies
PIN34-PIN41	265	Infection - Health Care Use & Policy Studies
PMS1-PMS3	269	Muscular-Skeletal Disorders - Clinical Outcomes Studies
PMS4-PMS12	270	Muscular-Skeletal Disorders - Cost Studies
PMS13-PMS16	274	Muscular-Skeletal Disorders - Patient-Reported Outcomes & Patient Preference Studies
PMS17-PMS21	276	Muscular-Skeletal Disorders - Health Care Use & Policy Studies

RESEARCH POSTER PRESENTATIONS - SESSION III

DISEASE- SPECIFIC STUDIES

CANCER - Clinical Outcomes Studies

- PCN1 A1 CHEMOTHERAPY, CYTOKINES AND CANCER-RELATED FATIGUE: A SYSTEMATIC REVIEW OF QUANTITATIVE STUDIES IN 1312 PATIENTS**
Woldehaimanot TE¹, Ng T¹, Chan A¹, Chan R^{2,1},¹National University of Singapore, Singapore, Singapore, ²Queensland University of Technology, Brisbane, Australia
- PCN2 A2 PREVALENCE OF COMORBIDITIES AND HEALTH STATUS AMONG CURRENT CANCER AND CANCER SURVIVORS: AN AUSTRALIAN POPULATION-BASED STUDY**
Ng HS, Roder D, Vitry A, University of South Australia, Adelaide, South Australia, Australia
- PCN3 A3 COMPARATIVE EVALUATION OF PRELIMINARY SCREENING METHODS FOR COLORECTAL CANCER IN A MASS SCREENING PROGRAM**
Ye D, Chen K, Huang Q, Zhejiang University, Hangzhou, China
- PCN4 A4 GEFITINIB, ERLOTINIB AND CHEMOTHERAPY AS SECOND-LINE TREATMENT FOR PATIENT WITH ADVANCED NON-SMALL LUNG CANCER (NSCLC)**
Yang M¹, Tan EC¹, Chen Y²,¹National Taiwan University, Taipei, Taiwan, ²Taipei Veterans General Hospital, Taipei, Taiwan
- PCN5 A5 A SYSTEMATIC REVIEW OF TYROSINE KINASE INHIBITORS AS FIRST LINE TREATMENT FOR ADVANCED NON SMALL CELL LUNG CANCER**
Kamaruzaman HF, Ku Abd Rahim KN, Lee SW, Mohd Darus N, Sabirin J, Ministry of Health Malaysia, Federal Territory of Putrajaya, Malaysia
- PCN7 A6 THE EFFECTIVENESS ANALYSIS OF SELECTED RADIOSURGERY DEVICES ON TREATMENT OF CANCER TUMORS AND ARTERIOVENOUS MALFORMATIONS: A SYSTEMATIC REVIEW**
Davari M¹, Afzali M¹, Sabbagh-Bani-Azad M¹, Sharif Z², Hadizadeh F³, Mirmoghtadaee P³, Bakrani A³, Hoseini SM⁴, Kollahdoozan F⁴,¹Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), ²Shahid-Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of), ³Isfahan University of Medical Science, Isfahan, Iran (Islamic Republic of), ⁴Medical image & signal processing research center, Isfahan, Iran (Islamic Republic of)
- PCN8 A7 PREVALENCE OF SHISHA SMOKING AMONG ADULT MALE CIGARETTE SMOKERS OF MULTAN, PAKISTAN**
Aziz MM¹, Fang Y¹, Ahmed J²,¹Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China, Xi'an, China, ²Eli Lilly Pakistan (PVT) LTD, Multan, Pakistan
- PCN9 A8 FACTORS INFLUENCING THE PHARMACOKINETICS OF SUNITINIB AND ITS ACTIVE METABOLITE IN MRCC PATIENTS RECEIVING AN ATTENUATED SUNITINIB DOSING REGIMEN**
Chae J, National University of Singapore, Singapore, Singapore
- PCN10 A9 REAL WORLD EXPERIENCE OF SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA; RESULTS FROM COMPASSIONATE USE PROGRAM IN MALAYSIA**
Lee YY¹, Lim TO², Hong LW¹,¹Pfizer Malaysia, Kuala Lumpur, Malaysia, ²StatsConsulting, Petaling Jaya, Malaysia
- PCN11 A10 PATIENT CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS WITH LIVER CANCER IN A TERTIARY-CARE HOSPITAL IN MALAYSIA**
Shabaruddin FH, Jamil AA, Hashim H, Yunus RM, Mohamed R, University of Malaya, Kuala Lumpur, Malaysia

CANCER - Cost Studies

- PCN12 B1 ECONOMIC EVALUATION OF CANCER MEDICINES USAGE AT UGANDA CANCER INSTITUTE**
Mwesige B, Uganda Cancer Institute, kampala, Uganda
- PCN13 B2 THE EVPI OF TREATMENT STRATEGIES FOR RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER**
Huang W¹, Chen L¹, Ting J¹, Cao V¹, Sung H¹, Yokokura M¹, Wilson L^{2,1},¹UCSF, San Francisco, CA, USA, ²University of California, San Francisco, San Francisco, CA, USA
- PCN14 B3 LITERATURE REVIEW ON HOSPITAL COSTS FOR PATIENTS UNDERGOING GASTRECTOMY**
Chen BP¹, Cheng H², Hsiao C²,¹Ethicon Inc., Somerville, NJ, USA, ²Global Health Economics and Market Access, Ethicon Inc., Cincinnati, OH, USA
- PCN15 B4 COST ANALYSIS OF DIFFERENT SEQUENTIAL TREATMENT REGIMENS FOR METASTATIC RENAL CELL CARCINOMA IN CHINA**
Wan Y¹, Gao C², Xue M¹, **Ren H³**, Dong P⁴,¹Pharmerit International, Bethesda, MD, USA, ²Pharmerit International, Newton, MA, USA, ³Pfizer China, Shanghai, China, ⁴Pfizer Investment Co., Ltd., Beijing, China
- PCN16 B5 BURDEN OF CANCERS ATTRIBUTABLE TO TOBACCO SMOKING IN MEMBER COUNTRIES OF THE ASSOCIATION OF SOUTH EAST ASIAN NATIONS (ASEAN), 2012**
Kristina SA¹, Endarti D¹, Thavorncharoensap M²,¹Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia, ²Mahidol

University, Bangkok, Thailand

- PCN17 B6 EFFECTS OF LAPAROSCOPIC SURGERY ON HEALTH OUTCOMES, HEALTH CARE UTILIZATION AND COST IN PATIENTS WITH COLON CANCER: A POPULATION-BASED STUDY USING PROPENSITY SCORE MATCHING**
Yang M¹, Tan EC¹, Chen C²,¹National Taiwan University, Taipei, Taiwan, ²Sun Yat-Sen Cancer Center, Taipei, Taiwan
- PCN19 B7 ECONOMIC BURDEN OF GEFITINIB VERSUS PEMETREXED FOR INSURED PATIENTS WITH LUNG CANCER IN URBAN XINJIANG PROVINCE, CHINA: A REAL WORLD RESEARCH**
MAO W, Chen W, Fudan University, Shanghai, China
- PCN20 B8 PHARMACOECONOMIC EVALUATION OF CANCER TREATMENTS IN INDIA**
Sundar S¹, Rajan S¹, Nagappa A²,¹Manipal University, Manipal, India, ²SCS College of Pharmacy, Harpanahalli, India
- PCN21 B9 COMPARISON OF COST-EFFECTIVENESS BETWEEN EGFR-TKIS THERAPY AND CHEMOTHERAPY FOR ADVANCED NSCLC**
Zhang T¹, Cai S¹, Wu C², Xu J¹, Lin T¹, Jiang J¹,¹Jinan University, Guangzhou, China, ²Sun Yat-sen Universtiy, Guangzhou, China
- PCN22 B10 CURRENT TRENDS IN METHODS OF PHARMACOECONOMIC STUDIES OF CANCER THERAPIES IN CHINA**
Ma F¹, Cheng X², Aballéa S³, Toumi M⁴,¹Creativ-Ceutical, Beijing, China, ²Creativ-Ceutical, Hong Kong, Hong Kong, ³Creativ-Ceutical, Paris, France, ⁴Aix-Marseille University, Marseille, France
- PCN23 C1 IMPLICATIONS OF PRICE EROSION OF DOCETAXEL AFTER LOSS OF EXCLUSIVITY ON COST-EFFECTIVENESS**
Kim H¹, Bae S², Liew D³,¹University of Melbourne, Parkville, Australia, ²Ewha Womans University, Seoul, South Korea, ³Monash University, Melbourne, Australia
- PCN24 C2 COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN TAIWAN**
Zou D¹, Kendall R¹, Lin Q², Huang Y², Tieng J³, Tseng J³, Sajosi P⁴,¹ICON plc, Vancouver, BC, Canada, ²Kantar Health, Taipei, Taiwan, ³Takeda Pharmaceuticals Taiwan, Taipei, Taiwan, ⁴Takeda Pharmaceuticals International AG, Zurich, Switzerland
- PCN26 C3 COST-EFFECTIVENESS OF RITUXIMAB IN THE TREATMENT OF DIFFUSE LARGE B-CELL NON-HODGKIN'S LYPHOMA PATIENTS (DLBCL) IN CHINA**
Chen W¹, Xu X²,¹Fudan University, Shanghai, China, ²Shanghai Roche Pharmaceuticals Ltd., Shanghai, China
- PCN27 C4 DON'T PUT OFF UNTIL TOMORROW WHAT YOU CAN DO TODAY: COST-EFFECTIVENESS OF TRASTUZUMAB PLUS PACLITAXEL COMBINATION THERAPY AND SEQUENTIAL USE OF PACLITAXEL AND TRASTUZUMAB IN THE TREATMENT OF METASTATIC BREAST CANCER IN SINGAPORE**
Pletscher M¹, Carreras M¹, Wong A², Doshi R²,¹Hoffmann-La Roche Ltd, Basel, Switzerland, ²Roche Singapore Pte Ltd, Singapore, Singapore
- PCN28 C5 THE CLINICAL AND ECONOMIC IMPACT OF SCHOOL-BASED QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE ON FEMALE OR BOTH GENDERS IN SINGAPORE**
Tay SK¹, **Hsu T**², Shcheprov A³, Walia A⁴, Kulkarni AS⁵,¹Singapore General Hospital, Singapore, Singapore, ²MSD Pharma (Singapore) Pte. Ltd., Singapore, Singapore, ³Merck & Co., Inc., Kenilworth, NJ, USA, ⁴MSD International GmbH (Singapore Branch), singapore, Singapore, ⁵Merck & Co. Inc, Rahway, NJ, USA
- PCN29 C6 OPTIMAL AND ENSURE TRIALS - BASED COMBINED COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS CHEMOTHERAPY FOR THE FIRST- LINE TREATMENT OF ASIAN PATIENTS WITH NONSQUAMOUS NON- SMALL-CELL LUNG CANCER**
Wen F¹, Zheng H¹, Zhang P¹, Hutton DW², Li Q¹,¹West China Hospital, Sichuan University, Chengdu, China, ²University of Michigan, Michigan, MI, USA
- PCN30 C7 COST-EFFECTIVENESS OF SURGICAL EXCISION VS MOHS MICROGRAPHIC SURGERY FOR NON-MELANOMA SKIN CANCER**
Maracy MR, Nasiripour L, Amirsadri MR, Tabatabaeian4 M, Isfahan University of Medical Sciences, Isfahan, Iran (Islamic Republic of)
- PCN31 C8 ECONOMIC EVALUATION OF CERVICAL CANCER SCREENING STRATEGIES IN CHINA**
Lu X¹, Chen W², Chen W³, Lang J⁴,¹Roche Diagnostics Limited, Shanghai, China, ²Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, ³Fudan University, Shanghai, China, ⁴Peking Union Medical College Hospital, Beijing, China
- PCN32 C9 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN PLUS FLUOROURACIL/LEUCOVORIN (FOLFOX4) COMPARED TO SORAFENIB FOR TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS IN CHINA**
Qin SK¹, Kruger E², Tan SC², Cheng SQ³, Yao XX⁴, Liang J⁵,¹Department of medical oncology, People's Liberation Army Cancer Center, Eight One Hospital, Nanjing, China, ²Economics and Outcomes, Real World Evidence, IMS Health, Singapore, ³Department of hepatic surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China, ⁴Health economic and outcome research, Sanofi, Shanghai, China, ⁵Department of medical oncology, Peking University tumor hospital, Peking University international hospital, Beijing, China
- PCN33 C10 COST EFFECTIVENESS OF BRCA MUTATION TESTING FOR EARLY-STAGE BREAST CANCER PATIENTS WITH FAMILY HISTORY IN MALAYSIA**

Lim KK¹, Yoon SY², Teo SH², Mohd Taib NA³, Shabaruddin FH³, Dahlui M³, Chaiyakunapruk N⁴,¹Duke NUS Medical School, Singapore, Singapore, ²Cancer Research Malaysia, Subang Jaya, Malaysia, ³University of Malaya, Kuala Lumpur, Malaysia, ⁴Monash University Malaysia, Selangor, Malaysia

PCN34 D1 TAMOXIFEN FOR THE PRIMARY PREVENTION OF BREAST CANCER: NEW LIFE FOR AN OLD DRUG

Alexander PR, Optum, Lilyfield, Australia

PCN35 D2 ECONOMIC EVALUATION OF FIRST LINE TREATMENT FOR ADVANCED NON SMALL CELL LUNG CANCER USING TYROSINE KINASE INHIBITORS IN MALAYSIA

Ku Abd Rahim KN¹, Kamaruzaman HF¹, Shafie AA², Hussain S³, Sabirin J¹,¹Ministry of Health Malaysia, Federal Territory of Putrajaya, Malaysia, ²Universiti Sains Malaysia, Penang, Malaysia, ³University of Malaya, Kuala Lumpur, Malaysia

PCN36 D3 A COST-UTILITY ANALYSIS OF THE RISK MODEL-GUIDED ANTIEMETIC PROPHYLAXIS VERSUS PHYSICIAN'S CHOICE IN PATIENTS RECEIVING CHEMOTHERAPY FOR EARLY-STAGE BREAST CANCER: A NET-BENEFIT REGRESSION APPROACH

Thavorn K¹, Vandermeer L², Mazzarello S², Wang Z³, Clemons M²,¹The Ottawa Hospital, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³University of Waterloo, Waterloo, ON, Canada

PCN37 D4 A TIME AND MOTION COST ANALYSIS OF ORAL VINORELBINE VERSUS IV CHEMOTHERAPIES FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND METASTATIC BREAST CANCER (MBC)FROM CHINESE SOCIETAL PERSPECTIVE

Zhang L¹, Crowell V¹, Ai X², Berdeaux G³, Zheng H⁴, Xuan J⁵,¹Shanghai Centennial Scientific, Shanghai, China, ²Shanghai Chest Hospital, Shanghai, China, ³Pierre Fabre Medicament, Boulogne-Billancourt, France, ⁴Shanghai Market Access Medicament Technology Developing Co.,Ltd, Shanghai, China, ⁵Sun Yat-Sen University, Guangzhou, China

CANCER - Patient-Reported Outcomes & Patient Preference Studies

PCN38 D5 A COMPARISON OF HEALTH STATE UTILITIES AMONG BREAST CANCER PATIENTS IN MAINLAND CHINA

Li S¹, Wang M², Xu X¹, Chen G³,¹Shandong University, Jinan, China, ²Qingdao Municipal Hospital, Qingdao, China, ³Flinders University, Adelaide, Australia

PCN39 D6 IMPACT OF PATIENTS COUNSELLING ON MINDFUL ATTENTION AWARENESS AND STRESS IN CANCER PATIENTS

Yiragamreddy SR, P.T.priyanka P, Yiragamreddy Pr,Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, India

PCN40 D7 BREAST CANCER IN JAPAN: ROOM FOR IMPROVED SCREENING

Vietri J¹, **Stankus AP**¹, Fukuda T²,¹Kantar Health, Horsham, PA, USA, ²National Institute of Public Health, Wako, Japan

PCN41 D8 PATIENT PREFERENCES VERSUS PHYSICIAN PERCEPTIONS OF TREATMENT DECISIONS IN ADVANCE STAGE PROSTATE CANCER

Yoshizawa K¹, **Mahlich J**¹, Nakayama M¹, Kobayashi H¹, Takahashi Y², Saito K², Tsubota A¹, Uemura H³, Masayuki T⁴,¹Janssen KK, Tokyo, Japan, ²ANTERIO Inc. ., Tokyo, Japan, ³Yokohama City University Medical Center, Yokohama-city, Japan, ⁴Kitasaito Hospital, Hokkaido, Japan

PCN42 D9 PREFERENCE FOR CERVICAL CANCER SCREENING IN RURAL CHINA: A DISCRETE CHOICE EXPERIMENT

Li S¹, Ratcliffe J², **Chen G**²,¹Shandong University, Jinan, China, ²Flinders University, Adelaide, Australia

PCN43 D10 DESIGNING A DISCRETE CHOICE EXPERIMENT TO MEASURE PATIENT PREFERENCES AND WILLINGNESS-TO-PAY FOR TARGETED THERAPIES FOR COLORECTAL CANCER IN SINGAPORE

Wong XY¹, Chia JW², Chew MH³, Tan WS³, Wee HL¹,¹National University of Singapore, Singapore, Singapore, ²National Cancer Centre Singapore, Singapore, Singapore, ³Singapore General Hospital, Singapore, Singapore

PCN44 E1 THE RELATIONSHIP BETWEEN REGRET IN PATIENT DECISION-MAKING DURING THE CLINICAL PROCESS AND PATIENT FACTORS—TESTS BASED ON THE JAPANESE VERSION OF THE DECISION REGRET SCALE(DRS)—

Tanno K¹, Bito S²,¹Rikkyo University, Tokyo, Japan, ²National Hospital Organization Tokyo Medical Center, Tokyo, Japan

PCN45 E2 PATIENT-REPORTED OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE OVERALL AND JAPANESE POPULATIONS FROM ELOQUENT-2

McKendrick J¹, Zyczynski T², Kudlac A¹, Davis C², **Cella D**³,¹PRMA Consulting Ltd, Fleet, UK, ²Bristol-Myers Squibb, Princeton, NJ, USA, ³Northwestern University, Chicago, IL, USA

PCN46 E3 PATIENT REPORTED OUTCOMES IN JAPANESE ONCOLOGY PRODUCTS - REVIEW OF THE PMDA LABELS

Crawford B¹, Kim HR²,¹IMS Japan K.K., Minato-ku, Tokyo, Japan, ²IMS Japan KK, Minato-ku, Tokyo, Japan

PCN47 E4 USING GEOGRAPHICAL INFORMATION SYSTEMS TO DESCRIBE QUALITY OF LIFE AS A FUNCTION OF DISTANCE IN CANCER PATIENTS

Hayran KM, Erman M, Kilickap S, Dizdar Ö, Yuce D, Huseyin B, Celik I,Hacettepe University Cancer Institute, Ankara, Turkey

CANCER - Health Care Use & Policy Studies

PCN48 E5 THE IMPACT OF CANCER PREVENTION AND TREATMENT POLICY ON INCREASING INCIDENCE OF EARLY-STAGE CANCER IN TAIWAN

Hsieh W, Kuo C, Lin Y, Chen C, Chang C, **Tang C**,Taipei Medical University, Taipei, Taiwan

- PCN49 E6 INFLUENCE OF COCHRANE EVIDENCE ON MEDICAL POLICIES OF ONCOLOGY DRUGS IN THE UNITED STATES**
Hussain S¹, Singh A², Najmi AK^{1,1}, Faculty of Pharmacy, Jamia Hamdard, Hamdard University, New Delhi, India, ²Independent Researcher, New Delhi, India
- PCN50 E7 COMPARISON OF THE TRENDS OF ORPHAN DRUGS DESIGNATIONS AND APPROVALS IN THE UNITED STATES AND EUROPE IN ONCOLOGY**
Hanna E¹, Korchagina D², Toumi M^{1,1}, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France, ²University of Paris-Sud, Paris, France
- PCN51 E8 CURRENT PRACTICE AND ATTITUDE REGARDING OFF-LABEL DRUG USE: A SURVEY OF ONCOLOGY PRACTITIONERS**
Saived MM, Ong PS, Chew L, National University of Singapore, Singapore, Singapore
- PCN52 E9 COMPARATIVE EFFECTIVENESS OF PLATINUM PLUS PACLITAXEL VERSUS PLATINUM PLUS CYCLOPHOSPHAMIDE AMONG PATIENTS WITH EARLY-STAGE OVARIAN CANCER IN TAIWAN**
Chen C¹, Tang C¹, Cheng W², You S³, Chiang C⁴, Chen Y⁵, ¹Taipei Medical University, Taipei, Taiwan, ²National Taiwan University Hospital, Taipei, Taiwan, ³Fu-Jen Catholic University, Taipei, Taiwan, ⁴National Taiwan University, Taipei, Taiwan, ⁵Taiwan Blood Services Foundation, Taipei, Taiwan
- PCN53 E10 ACCESS TO ANTI-CANCER DRUGS IN INDIA: IS THERE A NEED TO REVISE REIMBURSEMENT POLICIES?**
Haitsma G¹, Patel H², Parthasarathi G², Postma MJ^{1,1}, University of Groningen, Groningen, The Netherlands, ²JSS College of Pharmacy, Mysore, India
- PCN55 F2 EVALUATING PATIENT ACCESS TO TARGETED THERAPEUTICS AMIDST THE EVOLVING SINGAPOREAN HEALTH CARE LANDSCAPE**
Gardiner RB, Brahmabhatt H, Research Partnership, London, UK
- PCN56 F3 CAPACITY FOR ENDOSCOPIC SCREENING FOR GASTRIC CANCER IN JAPAN**
Hamashima C¹, Goto R^{2,1}, National Cancer Center, Tokyo, Japan, ²Kyoto University, Kyoto, Japan
- PCN57 F4 TREATMENT PATTERNS, BIOMARKER TESTING (BMX) PRACTICES AND HEALTHCARE RESOURCE USE (HCRU) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN TAIWAN**
Kothari S¹, Arunachalam A², Chen C^{3,1}, Merck & Co, Kenilworth, NJ, USA, ²Rutgers the State University of NJ, PISCATAWAY, NJ, USA, ³Merck Sharpe Dohme, TAIPEI, Taiwan
- PCN58 F5 GOVERNMENT SPONSORED HEALTH INSURANCE SCHEMES FOR REIMBURSEMENT OF CANCER TREATMENT IN INDIA**
Singh S, Rai MK, Bhutani MK, Singh R, Gollala M, Rana P, Tata Consultancy Services, Mumbai, India
- PCN59 F6 RISK SHARE AGREEMENTS (RSA), PRODUCT LISTING AGREEMENTS (PLA) OR PATIENT ACCESS SCHEMES (PAS) - ALL THE SAME OR DIFFERENT?**
Kim H¹, Harrison JP², Moshyk A³, **Liew D**^{4,1}, University of Melbourne, Parkville, Australia, ²Bristol-Myers Squibb, Uxbridge, UK, ³Bristol-Myers Squibb, Saint-Laurent, QC, Canada, ⁴Monash University, Melbourne, Australia
- PCN60 F7 EXPLORING PHARMACIST'S ROLE IN PALLIATIVE CARE: A QUALITATIVE STUDY**
Sundus A¹, **Gnanasan S**¹, Ismail NE^{2,1}, Universiti Teknologi MARA, Puncak Alam, Malaysia, ²MAHSA University, Selangor, Malaysia
- PCN61 F8 MAPPING THE POLICY RESPONSE TO BREAST CANCER IN ASIA**
Lovell AD, EIU Healthcare, London, UK
- PCN62 F9 PRIORITIZING MEDICATION PROBLEMS IN CARE OF PEOPLE WITH CANCER AND SOLUTIONS FOR THESE: A PRIORITIZE STUDY**
Tudor Car L, Imperial College London, London, UK
- PCN63 F10 IMATINIB DISCONTINUATION AND TKI SWITCHING PATTERNS IN THE RETROSPECTIVE AND PROSPECTIVE COHORTS IN SIMPLICITY, A STUDY OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS (PTS) IN ROUTINE CLINICAL PRACTICE**
Zyczynski T¹, Khoury J², Goldberg S³, Mauro M⁴, Michallet M⁵, Paquette R⁶, Foreman A⁷, Subar M¹, Turner M⁷, Manley Daumont M⁸, Hehlmann R⁹, Simonsson B^{10,1}, Bristol-Myers Squibb, Princeton, NJ, USA, ²Winship Cancer Institute of Emory University, Atlanta, GA, USA, ³John Theurer Cancer Center, Hackensack, NJ, USA, ⁴Memorial Sloan-Kettering Cancer Center, New York, NY, USA, ⁵Centre Hospitalier Lyon-Sud, Pierre-Bénite, France, ⁶UCLA Medical Centre, Los Angeles, CA, USA, ⁷ICON Clinical Research, San Francisco, CA, USA, ⁸Bristol-Myers Squibb, Paris, France, ⁹Universität Heidelberg, Mannheim, Germany, ¹⁰Uppsala Universitet, Uppsala, Sweden

DIABETES/ENDOCRINE DISORDERS - Clinical Outcomes Studies

- PDB1 G1 IS THERE AN ASSOCIATION BETWEEN DIABETIC MICROVASCULAR COMPLICATIONS AND SERUM CHOLESTEROL? A RETROSPECTIVE ANALYSIS AMONG MALAYSIAN PATIENTS WITH T2DM**
Abdul Aziz SH¹, Azmi S¹, Feisul MI², Abdat A¹, Goh A^{1,1}, Azmi Burhani Consulting, Petaling Jaya, Malaysia, ²Ministry of Health, Malaysia, Putrajaya, Malaysia
- PDB2 G2 PROTECTIVE EFFECT OF METFORMIN AGAINST TUBERCULOSIS IN DIABETIC PATIENTS**

- P S**, Marupuru S, Senapati P, Sekhar M S, MCOPS, Manipal University, Manipal, India
- PDB3 G3** **INDIRECT COMPARISON OF TRIAMCINOLONE ACETONIDE WITH RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF DIABETIC MACULAR EDEMA**
- Park S**, CHOI YR, Jeung S, Choi I, Suh D, Chung-Ang University, Seoul, South Korea
- PDB4 G4** **LIPID LEVELS AND GLYCAEMIC CONTROL IN MALAYSIAN DIABETES PATIENTS**
- Abdat A**¹, Azmi S¹, Feisul Mi², Goh A¹, Abdul Aziz SH¹,¹Azmi Burhani Consulting, Petaling Jaya, Malaysia, ²Ministry of Health, Malaysia, Putrajaya, Malaysia
- PDB5 G5** **DO MORE MEN OR WOMEN WITH T2DM ACHIEVE THEIR GLYCAEMIC TARGETS? AN EXPLORATORY MALAYSIAN STUDY**
- Azmi S**¹, Feisul Mi², Abdat A¹, Goh A¹, Abdul Aziz SH¹,¹Azmi Burhani Consulting, Petaling Jaya, Malaysia, ²Ministry of Health, Malaysia, Putrajaya, Malaysia
- PDB6 G6** **HEPARIN AND RELATED SUBSTANCES FOR TREATING DIABETIC FOOT ULCERS**
- Su N**, Xu T, West China Hospital of Sichuan University, Chengdu, China
- PDB7 G7** **EVALUATION OF GLYCEMIC CONTROL WITH THE COMBINATION OF BIPHASIC INSULIN AND METFORMIN THERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS**
- Sirajudeen SA**, King Khalid University, Abha, Saudi Arabia
- PDB8 G8** **IATROGENIC HYPOGLYCAEMIA IN THE ELDERLY: AN ANALYSIS OF DIABETIC MEDICATION USAGE PATTERNS ACCORDING TO AGE**
- Goh A**¹, Azmi S¹, Feisul Mi², Abdat A¹, Abdul Aziz SH¹,¹Azmi Burhani Consulting, Petaling Jaya, Malaysia, ²Ministry of Health, Malaysia, Putrajaya, Malaysia
- PDB9 G9** **NEED FOR ENHANCED GLUCOSE SCREENING IN PREGNANT WOMEN IN INDONESIA**
- Fitria N**, van Asselt A, Postma MJ, University of Groningen, Groningen, The Netherlands
- PDB10 G10** **PRESENCE OF LIPOHYPERTROPHY AND ITS RELATION TO INSULIN INJECTION PRACTICES IN PATIENTS WITH TYPE 1 DIABETES MELLITUS**
- Barola A**¹, Tiwari P¹, Bhansali A², Grover S²,¹National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India, ²Post Graduate Institute of Medical Education & Research, Chandigarh, India
- PDB11 H1** **RISK FACTORS OF CARDIOVASCULAR DISEASE IN MALAYSIAN DIABETES PATIENTS**
- Azmi S**¹, Feisul Mi², Abdat A¹, Goh A¹, Abdul Aziz SH¹,¹Azmi Burhani Consulting, Petaling Jaya, Malaysia, ²Ministry of Health, Malaysia, Putrajaya, Malaysia
- PDB12 H2** **METFORMIN TREATMENT AND HOMOCYSTEINE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS**
- Li S, Zhang Q, Li L, Li Q, Ren K, Yu C, Kwong J, **Sun X**, Li J, West China Hospital of Sichuan University, Chengdu, China
- PDB13 H3** **TIME TO DIABETES RELATED COMPLICATIONS FOR NEWLY DIAGNOSED DIABETES PATIENTS IN SINGAPORE**
- Saxena N**, Kannapiran P, Ang YG, National Healthcare Group, Singapore, Singapore, Singapore

DIABETES/ENDOCRINE DISORDERS - Cost Studies

- PDB14 H4** **GESTATIONAL DIABETES SCREENING FOR CHINESE WOMEN: A COST-EFFECTIVENESS ANALYSIS**
- Ming WK**, SUN YAT-SEN UNIVERSITY, Guangzhou, China
- PDB15 H5** **ESTIMATION OF NATIONAL ECONOMIC BURDEN OF HYPOGLYCAEMIA AMONG TYPE 2 DIABETES MELLITUS PATIENTS IN MALAYSIA**
- Aljunid SM**¹, Nur A², Ismail A², Aung YN³,¹Kuwait University, Kuwait City, Kuwait, ²Universiti Kebangsaan Malaysia, Cheras, Malaysia, ³UCSI University, Cheras, Malaysia
- PDB16 H6** **FACTORS ASSOCIATED WITH GLYCEMIC CONTROL AND DIABETES-RELATED COSTS IN PATIENTS WITH DIABETES IN THE UNITED ARAB EMIRATES: RESULTS FROM A RETROSPECTIVE LARGE CLAIMS DATA ANALYSIS**
- CHOI YC**, Lee YJ, Lee SH, Chang C, Song I, Suh D, Chung-Ang University, Seoul, South Korea
- PDB17 H7** **COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 50 VERSUS BIPHASIC HUMAN INSULIN 50 IN PEOPLE WITH TYPE 2 DIABETES MELLITUS IN CHINA**
- Wang H¹, Liu X², Wan L¹, Sun X¹, Chen K³, **Zhang Y**⁴,¹Yancheng Tinghu People's Hospital, Yancheng, China, ²Dongtai Peoples' Hospital, Yancheng, China, ³Jiangsu Funing Peoples' Hospital, Yancheng, China, ⁴Novo Nordisk(China) Pharmaceuticals Co., Ltd, Beijing, China
- PDB18 H8** **COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS ACARBOSE AS A MONOTHERAPY IN TYPE 2 DIABETES IN CHINA**
- Gu S**¹, Dong H²,¹Zhejiang University, Hangzhou, China, ²Zhejiang University, Hangzhou, China
- PDB19 H9** **THE COST-EFFECTIVENESS OF DULAGLUTIDE VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN**
- Lin H¹, Babineaux S², Lew T¹, Lowin J³, Lovato E³, **Strizek AA**⁴, Rajan N⁵,¹Eli Lilly and Company (Taiwan), Inc, Taipei, Taiwan, ²Eli Lilly and Company, Indianapolis, IN, USA, ³IMS Health, London, UK, ⁴Lilly Australia, Sydney, Australia, ⁵Eli Lilly

Australia, West Ryde, Australia

- PDB20 H10 COST-EFFECTIVENESS OF INSULIN DEGLUDEC TREATMENT IN PATIENTS WITH TYPE1 AND TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW**
Yue X¹, Guan HJ², Wu J³, Bai X³,¹University of Cincinnati, Cincinnati, OH, USA, ²Peking University China Center for Health Economic Research, Beijing, China, ³The 306th Hospital of PLA, Beijing, China
- PDB21 I1 COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN VERSUS GLIMEPIRIDE AS MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CHINA**
Shao H, Shi L, Tulane University, New Orleans, LA, USA
- PDB22 I2 COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS ACARBOSE AS SECOND-LINE THERAPY IN TYPE 2 DIABETES IN CHINA**
Gu S¹, Shao H², Zeng Y¹, Shi L², Dong H¹,¹Zhejiang University, Hangzhou, China, ²Tulane University, New Orleans, LA, USA
- PDB24 I3 REVIEW OF ECONOMIC EVALUATION OF SAXAGLIPTIN IN TYPE2 DIABETES IN CHINA**
Zhang C¹, HU C¹, Xu L²,¹Astrazeneca(China), Beijing, China, ²Astrazeneca (China), Beijing, China
- PDB25 I4 THE LONGTERM COST EFFECTIVENESS OF THE “COACHING PATIENTS ON ACHIEVING CARDIOVASCULAR HEALTH” (COACH) PROGRAM IN TYPE 2 DIABETES IN TASMANIA**
Palmer AJ¹, Vale MJ², Wells CL³, Ski C², Thompson DR², Si L⁴,¹Menzies Institute for Medical Research, Hobart, Australia, ²Australian Catholic University, Melbourne, Australia, ³Diabetes Tasmania, Hobart, Australia, ⁴University of Tasmania, Hobart, Australia

DIABETES/ENDOCRINE DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PDB26 I5 SELF-CARE BEHAVIOR AND MEDICATION USE OF BUDDHIST MONKS WITH DIABETES MELLITUS IN PHASI CHAROEN, BANGKOK**
Yensabai J¹, Torthear P¹, Neamsripetch V¹, Karndee A¹, Pongmesa T¹, Luckanajantachote P²,¹Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand, ²Department of Pharmacy, Samutsakhon Hospital, Samut Sakhon, Thailand
- PDB27 I6 ADHERENCE OF PATIENTS WITH TYPE 2 DIABETES TO MEDICATIONS – THE ROLE OF RISK PREFERENCES**
Simon-Tuval T¹, Shmueli A², Harman-Boehm I³,¹Ben-Gurion University of the Negev, Beer-Sheva, Israel, ²The Hebrew University of Jerusalem, Jerusalem, Israel, ³Ben-Gurion University of the Negev; Soroka University Medical Center, Beer-Sheva, Israel
- PDB28 I7 DISEASE RELATED KNOWLEDGE, MEDICATION ADHERENCE AND GLYCAEMIC CONTROL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PAKISTAN**
Nazir SU¹, Hassali MA², Saleem F²,¹School of Pharmaceutical Sciences, Penang, Malaysia, ²Universiti Sains Malaysia, Penang, Malaysia
- PDB29 I8 STUDY ON MEDICATION ADHERENCE BEHAVIOR AND QUALITY OF LIFE IN ELDERLY DIABETIC, HYPERTENSION PATIENTS IN A TERTIARY CARE HOSPITAL; A PROSPECTIVE STUDY**
katta Venkatesh R¹, M.M.Prabhu M², K.S.R. Pai KK³, Krishnadas K.Nandhakumar KK³,¹MCOPS,Manipal University, Manipal & BG Nagar, India, ²KMCH, Manipal university, Manipal, India, ³MCOPS,Manipal University, Manipal, India
- PDB30 I9 EFFECT OF A PAY-FOR-PERFORMANCE PROGRAM FOR DIABETES ON HEALTH STATUS (EQ-5D) IN TAIWAN**
Chen T¹, Lang HC²,¹Fu Jen Catholic University, NewTaipei, Taiwan, ²National Yang-Ming University, Taipei, Taiwan
- PDB31 I10 HIGHER WEIGHT, HIGHER BURDEN: OUTCOMES OF ADULTS IN JAPAN WITH TYPE 2 DIABETES**
Vietri J¹, Fukuda T², Stankus AP¹,¹Kantar Health, Horsham, PA, USA, ²National Institute of Public Health, Wako, Japan
- PDB32 J1 PREFERENCES FOR TREATMENT ATTRIBUTES OF DULAGLUTIDE AND LIRAGLUTIDE AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS AND THEIR WILLINGNESS TO SELF-INJECT DIABETES MEDICATION: A COMPARISON BETWEEN JAPAN AND THE UNITED KINGDOM**
Gelhorn HL¹, Bacci ED², Poon JL¹, Boye KS³, Suzuki SJ⁴, Babineaux S³,¹Evidera, Bethesda, MD, USA, ²Evidera, Seattle, WA, USA, ³Eli Lilly and Company, Indianapolis, IN, USA, ⁴Eli Lilly Japan KK, Kobe, Japan
- PDB33 J2 ASSESSMENT OF KNOWLEDGE AND PRACTICE REGARDING FOOT CARE OF DIABETES MELLITUS PATIENT IN TERTIARY CARE HOSPITALS, QUETTA, PAKISTAN**
ul Haq N, Durrani P, Nasim A, Razaque G, Ahmed N, Muhammad S, Raiz S,University of Balochistan, Quetta, Pakistan
- PDB35 J3 EFFECTIVENESS OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN REDUCING HBA1C OF DIABETES MELLITUS TYPE-2 PATIENTS IN JAKARTA, INDONESIA: PRELIMINARY FINDINGS**
Istanti ND,UNIVERSITY OF INDONESIA, INDONESIA, Indonesia
- PDB36 J4 TRANSLATION, ADAPTATION AND VALIDATION OF THE DIABETES DISTRESS SCALE FOR INDONESIAN DIABETIC OUTPATIENTS WITH VARIOUS TYPES OF COMPLICATIONS**
Arifin B¹, Perwitasari D², Atthobari J³, Cao Q⁴, Krabbe PF⁵, Postma MJ⁴,¹University of Groningen the Netherlands, Groningen, The Netherlands, ²University of Ahmad Dahlan Yogyakarta, Yogyakarta, Indonesia, ³Medical Faculty, Universitas Gadjah Mada, Yogyakarta, Indonesia, ⁴University of Groningen, Groningen, The Netherlands, ⁵University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- PDB37 J5 AN OBSERVATIONAL STUDY ON HEALTH RELATED QUALITY OF LIFE IN DIABETES MELLITUS PATIENTS**

Thunla Pr¹, Gundepogu UJ², Thumma P², Bairi R¹,¹St.peter's institute of pharmaceuticals sciences, Hanamkonda, India, ²St.peter's institute of pharmaceuticals sciences, hanamkonda, India

PDB38 J6 PSYCHOMETRIC PROPERTIES OF THE CHINESE VERSION OF PROBLEM AREAS IN DIABETES SCALE (SG-PAID-C) AMONG HIGH-RISK POLYPHARMACY PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES IN SINGAPORE

Siaw M¹, Tai B², Lee J¹,¹National University of Singapore, Singapore, Singapore, ²Caritas Institute of Higher Education and Caritas Bianchi College of Careers, Hong Kong, Hong Kong

PDB39 J7 INCREASING TREND OF HEALTH RELATED QUALITY OF LIFE AWARENESS FOR DIABETIC CARE AMONG INDIAN SCIENTISTS

Chawla R¹, **Katiyar P**¹, Hughes R², Purohit D¹,¹Accuscript Consultancy, Ludhiana, India, ²AccuScript Consultancy, Reading, UK

DIABETES/ENDOCRINE DISORDERS - Health Care Use & Policy Studies

PDB40 J8 MARKETING SITUATION AND MEDICAL REFORM POLICY ANALYSIS OF ORAL HYPOGLYCEMIC DRUGS IN CHINA

Long E¹, Zhou N², Yang N², **Hu M**², Zhou L²,¹Sichuan Provincial People's Hospital, Chengdu, China, ²Sichuan University, Chengdu, China

PDB41 J9 STUDY OF PRESCRIBING PATTERN OF ANTI-DIABETIC DRUGS IN NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS

Merry R¹, **Vijayanarayana K**¹, Girish T¹, Nair S¹, Karthik Rao N²,¹Dept. of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka State., India, ²Dept. of Medicine, Kasturba Medical College, Manipal University, Manipal, India

PDB42 J10 HEALTH CARE DIRECT COST BURDEN OF DIABETES IN MEDICARE BENEFICIARIES WITH OBESITY

Jaiswal R, University of the Sciences, Philadelphia, Philadelphia, PA, USA

PDB43 K1 ADMINISTRATIVE CLAIMS ANALYSIS OF ALL-CAUSE HEALTHCARE RESOURCE UTILIZATION FOR T2DM WITH CHRONIC COMORBIDITIES PATIENTS IN CHINA

Liu Q¹, Chen L², **Kong L**³, Hsiao C⁴, Yue N⁵,¹Beijing Brainpower Pharma Consulting Co.Ltd, Beijing, China, ²CHIRA, Beijing, China, ³London School of Economics and Political Science, London, UK, ⁴Global Health Economics and Market Access, Ethicon Inc., Cincinnati, OH, USA, ⁵Johnson & Johnson Medical Device, Beijing, China

PDB44 K2 PRESCRIPTION DATA IN AUSTRALIA: HOW USEFUL IS THIS 'BIG' DATA?

Kim H¹, Calcino L², Calcino G²,¹Bristol-Myers Squibb Australia, Mulgrave, Australia, ²HI Connections, Fisher, Australia

PDB45 K3 INFO-DIABETIC APPROACH FROM CELLULAR PHONE TEXT MASSAGING CAN MINIMIZE THE COMPLEXITIES IN DIABETIC PATIENT CARE

Kumar N, Gupta BK, Shri Ramswaroop Memorial University, Barabanki, India

PDB46 K4 DEVELOPMENT AND EVALUATION OF PATIENT INFORMATION LEAFLETS FOR DIABETIC FOOT ULCER PATIENTS

MK U¹, Miraj SS¹, Rodrigues GS²,¹Manipal College of Pharmaceutical Sciences, Manipal, India, ²Kasturba Medical College, Manipal, India

PDB47 K5 TREND IN HBA1C LEVELS AMONG PRIMARY CARE DIABETES PATIENTS ADMITTED TO A TERTIARY HOSPITAL IN SINGAPORE IN 2013

Ang YG, Teow KL, National Healthcare Group, Singapore, Singapore, Singapore

PDB48 K6 COMPARISONS OF TREATMENT PATTERNS FOR TYPE 2 DIABETES MELLITUS (T2DM) IN JAPAN AND IN THE UNITED STATES

Anabuki K¹, Irwin DE², Winer I³, Iizuka R¹, Nishikino R¹, Palmer LA⁴,¹Japan Medical Data Center Co.,Ltd., Tokyo, Japan, ²Truven Health Analytics, Chapel Hill, NC, USA, ³Truven Health Analytics, Ann Arbor, MI, USA, ⁴Truven Health Analytics, Bethesda, MD, USA

PDB49 K7 DEVELOPMENT OF ANTIBIOGRAM FOR MANAGEMENT OF AEROBIC BACTERIAL INFECTION IN DIABETIC FOOT ULCER

Miraj SS¹, MK U¹, Rodrigues GS²,¹Manipal College of Pharmaceutical Sciences, Manipal, India, ²Kasturba Medical College, Manipal, India

INDIVIDUAL'S HEALTH - Clinical Outcomes Studies

PIH1 K8 A COMPARISON OF LONG-TERM ANTICHOLINERGIC BURDEN DERIVED FROM DIFFERENT RISK SCALES WITH ADVERSE CLINICAL OUTCOMES IN THE ELDERLY

Hsu W¹, **Lin C**¹, Wen Y², Chen L³, Hsiao F¹,¹National Taiwan University, Taipei, Taiwan, ²Chang Gung University, Taoyuan, Taiwan, ³Taipei Veterans General Hospital, Taipei, Taiwan

PIH2 K9 EFFECT OF VIRUS HEPATITIS DURING PREGNANCY ON MATERNAL AND PERINATAL ADVERSE OUTCOMES: A SYSTEMATIC REVIEW BASED ON OBSERVATIONAL STUDIES

Tan J¹, Sun X²,¹School of West China Public Health, Sichuan University, Chengdu, China, ²West China Hospital of Sichuan University, Chengdu, China

PIH3 K10 PREVALENCE, PHARMACEUTICAL EXPENDITURES AND PATIENT'S FACTORS OF HIGH-RISK MEDICATION USED AMONG ELDERLY INPATIENTS AT A DISTRICT HOSPITAL IN THE SOUTH OF THAILAND

Jantakanangkoon C, Ninlamote W, **Pannoi T**, Walailak University, Nakhorn-Sri-Thammarat, Thailand

PIH4 L1 **PREVALENCE OF LOW BIRTHWEIGHT AND ITS CORRELATES FROM 2008 TO 2014 IN XINDU COUNTY OF CHENGDU, CHINA**

Zhu P, Pan X, Wang Y, Li C, Chen J, Sichuan University, Chengdu, China

INDIVIDUAL'S HEALTH - Cost Studies

PIH5 L2 **ECONOMIC ASSESSMENT OF DYDROGESTERONE COMPARED WITH PROGESTERONE FOR THE TREATMENT OF THREATENED AND HABITUAL MISCARRIAGE IN CHINA**

Connolly M¹, Tian Q², Sierra M³, **Zhang L**⁴, Vaskantiras V⁵,¹University of Groningen, Groningen, The Netherlands, ²Peking Union Medical College Hospital, Beijing, China, ³Global Market Access Solutions, St-Prex, Switzerland, ⁴Abbott China, Shanghai, China, ⁵Abbott Products Operations AG, Basel, Switzerland

PIH6 L3 **SUPPLEMENTING THE RIGHT WAY: EFFECTIVE COST MANAGEMENT OF MULTIVITAMIN SYRUPS IN A PAEDIATRIC HOSPITAL**

Lim KS, Caleb JS, KK Women's and Children's Hospital, Singapore, Singapore

PIH7 L4 **REAL-WORLD EVIDENCE IN THE CONTEXT OF HTA: ON THE EXAMPLE OF UTERINE FIBROIDS TREATMENT IN UKRAINE**

Piniashko O, Zaliska O, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PIH8 L5 **DRUG UTILIZATION AND PHARMACOECONOMIC ANALYSIS OF GERIATRIC PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL**

Mohamed Saleem TS, Gopinath C, Mahesh K, Sharmila Bhanu T, Annamacharya College of Pharmacy, YSR Kadapa, India

PIH9 L6 **COST-MINIMIZATION ANALYSIS OF BAOFUKANG VERSUS LANGYI IN THE TREATMENT OF VVC**

SUN L, Duan X, LU Y, Chen Y, Shenyang Pharmaceutical University, shenyang, China

INDIVIDUAL'S HEALTH - Patient-Reported Outcomes & Patient Preference Studies

PIH10 L7 **MEASURING THE INFLUENCE OF PATIENT COUNSELING AT TERTIARY CARE HOSPITAL IN ANTENATAL CARE, SOUTH KARNATAKA, INDIA**

Udupa N, Manipal University, Manipal, India

PIH11 L8 **PROJECT OCTO-PILLS: MANAGEMENT OF POLYPHARMACY AND DRUG RELATED PROBLEMS FROM HOSPITAL TO COMMUNITY PHARMACIES – AN OCTOPUS INITIATIVE FOR THE SILVER TSUNAMI**

Low YT¹, Neo ZY², Chong BK¹, Ong KY², Lim KW², Heng GE², Chan M¹, Chung WL¹, Lim ZN¹, Teo D², Wong JA², Tan MC², Kong MC², Mamun K², Chen LL²,¹Watson's Personal Care Stores Pte Ltd, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore

PIH12 L9 **SELF-REPORTED SLEEP QUALITY, DURATION AND HEALTH-RELATED QUALITY OF LIFE IN OLDER CHINESE**

Wang P, National University of Singapore, Singapore, Singapore

PIH13 L10 **THE GUARDIANS' CHOICES AND PREFERENCES FOR IMPORTED SURROGATE VACCINES IN CHINA: BASED ON A SURVEY IN SHENYANG, LIAONING PROVINCE**

Hao Y, Sun L, Jia Y, Li R, Hua S, Duan X, Li Y, Shang Y, Tang M, Shenyang Pharmaceutical University, Shenyang, China

PIH14 M1 **ASSESSMENT OF VARIOUS FACTORS INFLUENCING QUALITY OF LIFE IN PCOS PATIENTS OF NORTHERN TELANGANA REGION OF INDIA**

Talla V¹, Jupally vR², Subudhi S³, Hunsur Nagendra V¹, Velupula S², Thatikonda K²,¹Talla Padmavathi College of Pharmacy, Warangal, India, ²Talla Padmavathi College of Pharmacy, Warangal, INDIA, WARANGAL, India, ³Talla Padmavathi Pharmacy College, Warangal, WARANGAL, India

PIH15 M2 **USING A DISCRETE CHOICE EXPERIMENT TO VALUE INFORMAL CARE PROVIDED TO CHILDREN WITH INTELLECTUAL DISABILITIES**

Arora S¹, Goodall S¹, Viney R¹, Einfeld S²,¹University of Technology Sydney, Sydney, Australia, ²University of Sydney, Sydney, Australia

INDIVIDUAL'S HEALTH - Health Care Use & Policy Studies

PIH16 M3 **ANALYSIS OF PATIENTS' SATISFACTION ON THE IMPLEMENTATION OF ESSENTIAL DRUG SYSTEM IN CHINA**

Ren JP, Hangzhou Normal University, HANGZHOU, China

PIH17 M4 **CHANGING PATTERNS OF MEDICATION USE AT THE END OF LIFE IN THE ELDERLY**

Chuang H¹, Hsiao F²,¹National Taiwan University, Taipei, Taiwan, ²Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

PIH18 M5 **IMPACT OF POVERTY ON HEALTH CARE UTILIZATION IN THE ELDERLY**

Lin C, Hsiao F, National Taiwan University, Taipei, Taiwan

PIH19 M6 **THE EFFECT OF REDUCING COST-SHARING FOR CHILDREN ON UTILIZATION OF INPATIENT SERVICES: EVIDENCE FROM JAPAN**

Kato H¹, Goto R²,¹Kyoto University, Kyoto, Japan, ²Keio University, Yokohama, Japan

PIH20 M7 **The association between loneliness and healthcare utilization among older adults in Singapore**

Lim KK, Chan A, Duke NUS Medical School, Singapore, Singapore

- PIH21 M8 THE ADOPTION TRENDS OF ROBOTIC-ASSISTED BENIGN HYSTERECTOMY IN UNITED STATES FROM 2008 TO 2014**
Moawad G¹, Song C², Lavin J², Tackett S³, **Liu E**^{2,1}, George Washington University, Washington, DC., DC, USA, ²Intuitive Surgical, Sunnyvale, CA, USA, ³Intuitive Surgical, Inc., Sunnyvale, CA, USA
- PIH23 M9 HOUSEHOLD COST OF INJURIES IN CHILDREN UNDER FIVE YEARS IN THE EJISU-JUABENG MUNICIPALITY OF THE ASHANTI REGION, GHANA: A CROSS SECTIONAL STUDY**
Amisshah J, Kwame Nkrumah University of Science and Technology, KUMASI, Ghana
- PIH24 M10 TRADITIONAL AND COMPLEMENTARY MEDICINE USE AMONG WOMEN TO CONCEIVE AND DURING PREGNANCY: A LITERATURE REVIEW**
Shaukat Ali R¹, **Farooqui M**¹, Gnanasan S^{2,1}, Universiti Teknologi MARA (Bertam campus), Penang, Malaysia, ²Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Malaysia
- PIH25 N1 CLINICAL AND ECONOMIC OUTCOMES OF PHARMACIST-PROVIDED HOME-BASED MEDICATION REVIEW IN THE ELDERLY: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Tan SY¹, Cheen HH², Wee HL^{1,1}, National University of Singapore, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore
- PIH26 N2 ASSOCIATION BETWEEN SUBJECTIVE WELL-BEING AND HEALTH STATUS AMONG THE ELDERLY IN CHINA: THE INFLUENCES OF SOCIAL SUPPORT AND SOCIAL ADJUSTMENT**
Bao C¹, Chen K^{2,1}, Zhejiang University, Hangzhou, Zhejiang, China, ²Zhejiang University, Hangzhou, China
- PIH27 N3 RELATIONSHIP BETWEEN PERCEPTION OF SEX HORMONES IMBALANCE, DEPRESSION AND COGNITIVE FUNCTION AMONG FEMALE STUDENTS IN INTERNATIONAL MEDICAL UNIVERSITY: A CROSS-SECTIONAL STUDY**
Tumkur A, Venkataraman R, Mittal P, Koay LS, Chiam SE, Choong SP, Chow SY, International Medical University, Kuala Lumpur, Malaysia
- PIH28 N4 IMPACT OF SAFETY-RELATED REGULATION ON USE OF CODEINE IN TAIWANESE CHILDREN**
Lin C¹, Wang C¹, Huang W¹, Ke W¹, Chao P¹, Chen W¹, Hsiao F^{2,1}, Taiwan Drug Relief Foundation, Taipei, Taiwan, ²National Taiwan University, Taipei, Taiwan

INFECTION - Clinical Outcomes Studies

- PIN2 N6 REVIEWING THE ECONOMIC IMPACT OF EXTENDING THE NATIONAL IMMUNIZATION PROGRAM IN EGYPT**
Atef M, **Khataby N**, Ministry of Health, Cairo, Egypt
- PIN3 N7 EFFECT OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, ANGIOTENSIN II RECEPTOR BLOCKERS, AND STATINS ON SEPSIS-RELATED OUTCOMES**
Suh JK¹, Lee S^{2,1}, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, ²Seoul National University Hospital, Seoul, South Korea
- PIN4 N8 AUSTRALIAN INFLUENZA NATIONAL SURVEILLANCE DATA (2009 TO 2014) – VARIATIONS BY SEX, AGE GROUP, AND INFLUENZA TYPE**
Wong KC¹, Luscombe G^{2,1}, Western Sydney University, Bathurst, NSW, Australia, ²University of Sydney, Orange, NSW, Australia
- PIN5 N9 DISEASE BURDEN OF HERPES ZOSTER IN TAIWAN: A FIVE-YEAR POPULATION-BASED STUDY**
Lu W¹, **Chuang H**¹, Chen L², Hsiao F^{1,1}, National Taiwan University, Taipei, Taiwan, ²Taipei Veterans General Hospital, Taipei, Taiwan
- PIN6 N10 LONGITUDINAL TREND OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVALENCE RATES IN THE UNITED STATES**
Song X, Truven Health Analytics, Shrewsbury, MA, USA
- PIN7 O1 A RETROSPECTIVE OBSERVATIONAL COHORT STUDY TO INVESTIGATE TREATMENT OUTCOME OF MRSA PATIENTS ADMINSTRATED WITH ANTI-MRSA DRUGS USING LARGE INSURANCE CLAIMS DATA IN JAPAN**
Yuasa A¹, Murata T², Kitazaki S³, Ii Y¹, Yamamoto Y³, Fujimoto Y^{1,1}, Pfizer Japan Inc, Tokyo, Japan, ²CRECON Medical Assessment Inc., Tokyo, Japan, ³MinaCare co.ltd, Tokyo, Japan
- PIN8 O2 DETERMINATION OF PREDICTORS OF PROLONGED HOSPITALIZATION AMONG DENGUE PATIENTS ATTENDING TERTIARY CARE HOSPITAL IN MALAYSIA**
Mallhi TH¹, Khan AH², Sarriff A², Adnan AS³, Khan YH^{2,1}, University Sains Malaysia, Pulau Penang, Malaysia, ²Universiti Sains Malaysia, Pulau Pinang, Malaysia, ³University Sains Malaysia, Kota Bharu, Malaysia
- PIN9 O3 A STUDY ON EVALUATION OF EFFECTS OF ANTI-TUBERCULAR DRUGS ON HEMATOLOGICAL AND HEPATO-RENAL FUNCTIONS IN TUBERCULOSIS PATIENTS**
Sagar SV, Bodasu M, Pasunoori R, Adepu S, Vurumadla S, St. Peter's Institute of Pharmaceutical Sciences, Hanamkonda, India

INFECTION - Cost Studies

- PIN10 O4 ASSESSING THE BROADER ECONOMIC CONSEQUENCES OF HPV PREVENTION IN INDONESIA USING A GOVERNMENT PERSPECTIVE FISCAL ANALYTIC METHOD**
Setiawan D¹, Kotsopoulos N², Postma M¹, Connolly M^{3,1}, University of Groningen, Groningen, The Netherlands, ²Health Policy

Institute, Athens, Greece, ³Global Market Access Solutions, Switzerland and US, Groningen, The Netherlands

- PIN11 O5** **ROLE OF TIERED PRICING POLICY IN IMPROVING ACCESS TO MEDICINES IN INDIA**
Soni P¹, Gupta SK²,¹Delhi Institute of Pharmaceutical Sciences & Research, Delhi, India, ²Delhi Institute of Pharmaceutical Sciences and Research, University of Delhi, India., Delhi, India
- PIN13 O6** **Cost analysis of levofloxacin 750mg during 5 days vs levofloxacin 500mg during 10 days for the treatment of community-acquired pneumonia under the brazilian public hospital perspective**
Tolentino AC¹, Seabra E², Tanaka E³,¹Hospital Universitario Pedro Ernesto - UERJ/HUPE, Rio de Janeiro, Brazil, ²Hospital universitario Pedro Ernesto, Rio de Janeiro, Brazil, ³CURITIBA'S HEALTH INSTITUTE, CURITIBA , PARANÁ, Brazil
- PIN14 O7** **DIRECT MEDICAL COSTS OF HCV PATIENTS USING NATIONAL HEALTH INSURANCE CLAIMS DATA IN SOUTH KOREA**
Kang D, Lim J, Shin G, Bae E, Choi S, Korea University, Sejong city, South Korea
- PIN15 O8** **ECONOMIC BURDEN OF ANTIBIOTIC-RESISTANT NOSOCOMIAL GRAM-NEGATIVE INFECTIONS IN SINGAPORE HOSPITALS**
Chen G¹, Lim S¹, Ma Q¹, Ghosh W²,¹Costello Medical Singapore Pte Ltd, Singapore, Singapore, ²Costello Medical Consulting Ltd, Cambridge, UK
- PIN16 O9** **ECONOMIC EVALUATION OF DENGUE VACCINATION IN BANGKOK METROPOLITAN ADMINISTRATION**
Liulak W¹, Chuenkitmongkol S², Thongsri W², Beucher S³, Baurin N⁴, Thisyakorn U⁵,¹Health Department ,Bangkok Metropolitan Administration, Bangkok, Thailand, ²Sanofi Pasteur, Bangkok, Thailand, ³Sanofi Pasteur, Singapore, Singapore, ⁴Sanofi Pasteur, Lyon, France, ⁵Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- PIN17 O10** **TREATMENT PATTERN OF ANTIBIOTICS AND COST ANALYSIS IN SEPSIS PATIENTS: A CROSS SECTIONAL RETROSPECTIVE & PROSPECTIVE STUDY**
Erraboina M¹, Gopagoni K¹, Manthen A¹, Bandari S², Vurumadla S²,¹St.Peter's Institute of Pharmaceutical Sciences, Hanamkonda, India, ²St Peter's Institute of Pharmaceutical sciences, Hanamkonda, India
- PIN18 P1** **ECONOMIC BURDEN OF COMMUNITY-ACQUIRED PNEUMONIA AMONG ELDERLY**
Konomura K¹, Nagai H², Akazawa M¹,¹Meiji Pharmaceutical University, Tokyo, Japan, ²National Hospital Organization Tokyo National Hospital, Tokyo, Japan
- PIN19 P2** **CRITICAL ISSUES INFLUENCING COST-EFFECTIVENESS ANALYSES OF PNEUMOCOCCAL VACCINE STRATEGY FOR ELDERLY IN JAPAN**
Takumoto Y¹, Akazawa M¹, Igarashi A²,¹Meiji Pharmaceutical University, Tokyo, Japan, ²University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan
- PIN20 P3** **COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS VORICONAZOLE IN THE EMPIRICAL ANTIFUNGAL THERAPY OF FEBRILE NEUTROPENIA IN CHINA**
Wei Y, Chen Y, Guo Z, Fudan University, Shanghai, China
- PIN21 P4** **A PARALLEL OBSERVATIONAL AND PROSPECTIVE STUDY ON PHARMACOECONOMIC ANALYSIS AND PRESCRIBING PATTERN OF ANTIBIOTICS IN INFECTIOUS DISEASES**
Chenna C¹, Bandari S², Pal M³, Gaddam D⁴,¹St peter's Institute of Pharmaceutical sciences, Warangal, India, ²St.Peter's Institute of Pharmaceutical Sciences, Warangal, India, ³St.Peter's Institute of Pharmaceutical Sciences, Warangal, Telangana, India, ⁴St Peter's Institute of Pharmaceutical science, Warangal, India
- PIN22 P5** **ECONOMIC EVALUATIONS OF HAEMOPHILUS INFLUENZAE TYPE B VACCINE: A SYSTEMATIC REVIEW**
Chongmelaxme B¹, Hammanee M², Phooaphirak W², Kotirum S², Chaiyakunapruk N²,¹Naresuan University, Phitsanulok, Thailand, ²Monash University Malaysia, Selangor, Malaysia
- PIN23 P6** **ECONOMIC EVALUATION OF PROTEASE INHIBITORS FOR THE TREATMENT OF PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C IN KAZAKHSTAN**
Almadiyeva A¹, Ibrayev S¹, Turgambayeva A¹, Nurgozhin T²,¹Astana Medical University, Astana, Kazakhstan, ²Nazarbayev University, National Laboratory Astana, Astana, Kazakhstan
- PIN24 P7** **COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION IN HANGZHOU, CHINA: A COMPARISON BETWEEN TWO VACCINES**
Suwantika AA¹, Postma MJ²,¹Universitas Padjadjaran, Sumedang, Indonesia, ²University of Groningen, Groningen, The Netherlands
- PIN25 P8** **COST-EFFECTIVENESS OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AS ADJUNCTIVE THERAPY IN CANCER PATIENTS WITH ESTABLISHED FEBRILE NEUTROPENIA**
Tong WX, **Wang XJ**, Chan A, National University of Singapore, Singapore, Singapore
- PIN26 P9** **COST-EFFECTIVENESS ANALYSIS OF IMPROVED INFLUENZA VACCINATION COVERAGE IN ADULTS AGED 60 YEARS AND OLDER IN BEIJING, CHINA**
Cheng X¹, Aballea S², Dorey J², Zhou J³, Jia Y⁴, Toumi M⁵,¹Creativ-Ceutical, Hong Kong, Hong Kong, ²Creativ-Ceutical, Paris, France, ³Creativ-Ceutical, Beijing, China, ⁴Shenyang Pharmaceutical University, Shenyang, China, ⁵Aix-Marseille University, Marseille, France
- PIN27 P10** **COST-UTILITY ANALYSIS OF ATAZANAVIR/RITONAVIR 200/100 MG VERSUS ATAZANAVIR/RITONAVIR 300/100 MG IN**

THAI ADULTS WITH VIROLOGIC SUPPRESSION

Taychakhoonavudh S¹, **Maneesawangwong N**¹, Bunupuradah T², Kiertiburanakul S³, Worrathammasorn T¹, Hadnorntun P¹, Avihingsanon A², Chetchotisakd P⁴, Emery S⁵, Ruxrungtham K, on behalf of the LASA Study Group⁶, ¹Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand, ²HIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand, ³Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, Bangkok, Thailand, ⁴Khon Kaen University, Khon Kaen, Thailand, ⁵Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia, ⁶HIV-NAT, the Thai Red Cross AIDS Research Centre and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

PIN28 Q1 CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH HOSPITAL-ACQUIRED PNEUMONIA (HAP)

Han S¹, Xie J², Song H¹, Zhang C¹, Wu EQ³, ¹Analysis Group, Inc., Beijing, China, ²Analysis Group, Inc., New York, NY, USA, ³Analysis Group, Inc., Boston, MA, USA

INFECTION - Patient-Reported Outcomes & Patient Preference Studies

PIN29 Q2 MEDICATION ADHERENCE AND RISK FACTORS FOR NONADHERENCE AMONG HIV POSITIVE PREGNANT WOMEN TAKING TENOFOVIR BASED FIXED DOSE COMBINATION REGIMEN IN NIGERIA

Omonaiye O, AGU KA, WEST AFRICAN POST GRADUATE COLLEGE OF PHARMACISTS, LAGOS, Nigeria

PIN30 Q3 ROLE OF TUBERCULOSIS HOME OBSERVER IN IMPROVING CLINICAL OUTCOME OF PATIENT IN YEMEN

Jaber AA, Universiti Sains Malaysia, Penang, Malaysia

PIN31 Q4 ANTIMICROBIAL AGENTS DISPENSING IN UPPER RESPIRATORY TRACT, GASTROINTESTINAL TRACT INFECTIONS AND INFECTED WOUND IN THAI DRUG STORES IN 2015

Hemrachatanant P¹, Kajitpornwadee T¹, Korntanasin T¹, Auamnoy T², **Pongpech P**¹, ¹Chulalongkorn University, Bangkok, Thailand, ²Burapha University, Chonburi, Thailand

PIN32 Q5 EVALIATION OF UTILITY INDEX OF QUALITY OF LIFE IN HEPATITIS PATIENTS IN JAPAN

Yoda T¹, Igarashi A², Sugimori H³, Sato T⁴, Hirao T¹, ¹Kagawa University, Faculty of Medicine, Kagawa, Japan, ²University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, ³Daito Bunka University, Tokyo, Japan, ⁴Aoyama Gakuin University, Tokyo, Japan

PIN33 Q6 THE PUBLIC ACCEPTANCE AND WILLINGNESS-TO-PAY (WTP) OF DENGUE VACCINE IN PENANG, MALAYSIA: ASSESSMENT WITH A CONTINGENT VALUATION STUDY

Yeo HY, Shafie AA, Universiti Sains Malaysia, Penang, Malaysia

INFECTION - Health Care Use & Policy Studies

PIN34 Q7 KNOWLEDGE AND PERCEPTION OF MEDICINE, DENTISTRY AND PHARMACY STUDENTS OF MALAYSIAN UNIVERSITY REGARDING EBOLA VIRUS DISEASE (EVD)

Iqbal MZ¹, Iqbal MS², **Deneshwary B**³, Rahul RR¹, Muhammad Tahir M⁴, Yeoh CC³, Aziz S³, Mohiuddin SG³, ¹AIMST University, Bedong, Kedah Darul Aman, Malaysia, Malaysia, ²MAHSA University, Kuala Lumpur, Malaysia, ³AIMST University, Sungai Petani, Malaysia, ⁴University of Veterinary and Animal Sciences, Lahore, Pakistan., Lahore, Malaysia

PIN35 Q8 PREDICTORS OF RESPONSE TO INTERFERONE/ RIBAVARIN COMBINATION THERAPY IN CHRONIC HEPATITIS C VIRUS INFECTION AT UPPER EGYPT

Kassem AM, Sohag Faculty of Medicine, Sohag, Egypt

PIN36 Q9 EVALUATION OF ANTIMICROBIAL STEWARDSHIP PROGRAMS IN HAINAN, CHINA

Zhou H, Hainan Medical University, Haikou, China

PIN37 Q10 COMMUNITY RESIDENTS' KNOWLEDGE AND PERCEPTIONS OF ANTIBIOTIC RESISTANCE IN PENANG, MALAYSIA: FINDINGS AND IMPLICATIONS

Irawati L¹, Hassali MA¹, Saleem F¹, Alrasheedy AA², ¹Universiti Sains Malaysia, Penang, Malaysia, ²Qassim University, Qassim, Saudi Arabia

PIN38 R1 COST OF OUTREACH-PROGRAMME TOWARD SEX WORKERS IN THE NGO AND PRIMARY HEALTH CENTER IN INDONESIA

Sucahya pK¹, Nadjib M², Oktarina R², ¹Center for Health Research Universitas Indonesia, Depok, Indonesia, ²Universitas Indonesia, Depok, Indonesia

PIN39 R2 DEVELOPING A GEOSPATIAL WEB AND MOBILE APPLICATION TO IMPROVE EXPANDED PROGRAM ON IMMUNIZATION IN GHANA: A MHEALTH TECHNOLOGY NOVELTY, 2015

Antoh E¹, Davies-Teye B², Vanotoo L³, ¹GeoGrafix Solutions and USAID GHANA/RING, Accra, Ghana, ²Drifney Consult Ltd and Ghana Health Service, Accra, Ghana, ³Ghana Health Services and Promise Ghana, Accra, Ghana

PIN40 R3 INTEGRATION OF HIV AIDS PROGRAM INTERVENTION INTO UNIVERSAL HEALTH COVERAGE (UHC) : LESSON LEARNED FROM INDONESIA

Nadjib M¹, Sucahya P¹, Korib M¹, Harimurti P², Pujiyanto P¹, Octarina R¹, Megraini A¹, ¹Universitas Indonesia, Depok, Indonesia, ²World Bank, Jakarta, Indonesia

PIN41 R4 APPROACH TO IMPLEMENTATION OF A FEASIBLE ANTIBIOTIC STEWARDSHIP PROGRAM AT A TERTIARY UNIVERSITY PUBLIC HOSPITAL

MUSCULAR-SKELETAL DISORDERS - Clinical Outcomes Studies

- PMS1 R5 ACUTE CARDIOVASCULAR ADVERSE REACTION OF COX-2 INHIBITORS AMONG OSTEOARTHRITIS PATIENTS IN TAIWAN**
Chang C¹, Wang Y¹, Huang Y², Fann CS³, Chang CJ^{1,1}, Chang Gung University, Tao-Yun, Taiwan, ²Kantar Health, Taipei, Taiwan, ³Academia Sinica, Taipei, Taiwan
- PMS2 R6 CLINICAL EVALUATION OF AMRITHA GUGGULU IN THE MANAGEMENT OF GOUT**
Kuvettu H¹, Acharya S², Nagappa AN^{3,1}, Muniyal Institute Of Ayurveda Medical Sciences, Manipal., Mangalore, India, ²PG Dept. of Kayachikitsa, Muniyal Institute of Ayurveda Medical Sciences, Manipal, India, ³Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
- PMS3 R7 THE EFFECTIVENESS OF LEAN BODY MASS ANALYSIS USING DUAL ENERGY X-RAY ABSORPTIOMETRY (DEXA) FOR DIAGNOSIS OF SARCOPENIA**
Kim SY, National Evidence-based Collaborating Agency, Seoul, South Korea

MUSCULAR-SKELETAL DISORDERS - Cost Studies

- PMS4 R8 THE COMPARISONS OF BIOLOGICS WITH METHOTREXATE FOR TREATING RHEUMATOID ARTHRITIS PATIENTS IN TAIWAN: THE USE OF COST-UTILITY ANALYSIS AND BUDGET IMPACT ANALYSIS**
Li C¹, Chou P², Chang C³, Fann CS^{4,1}, Chang Gung University, Taichung, Taiwan, ²IMS Health Taiwan, Taipei City, Taiwan, ³Chang Gung University, TaoYuan, Taiwan, ⁴Academia Sinica, Taipei, Taiwan
- PMS5 R9 RISK AND BURDEN OF SUBSEQUENT FRACTURES AFTER FIRST OSTEOPOROSIS-RELATED FRACTURE AMONG OSTEOPOROSIS PATIENTS IN TIANJIN, CHINA**
Liu X¹, Wang K², Chen Y², Wu J^{1,1}, Tianjin University, Tianjin, China, ²Lilly Suzhou Pharmaceutical Company, Ltd., Shanghai, China
- PMS6 R10 BURDEN OF OSTEOPOROSIS-RELATED HIP FRACTURE IN ASIA. A REVIEW OF HEALTH CARE COSTS AND RESOURCE UTILIZATION**
Mohd Tahir NA¹, Thomas P², Li SC^{1,1}, University of Newcastle, Callaghan, NSW, Australia, ²Taylor's University, Selangor, Malaysia
- PMS7 S1 EVALUATION OF HEALTH CARE COSTS AND UTILIZATION PATTERNS FOR PATIENTS WITH GOUT IN TAIWAN**
Lee Y¹, Ko Y², Wu C³, Tang C², Kuo L^{1,1}, Taipei Medical University and Wan Fang Hospital, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Taipei Medical University, Taipei City, Taiwan
- PMS8 S2 HOSPITAL ADMISSIONS AND INPATIENT COSTS OF NON-UNION, DELAYED UNION AND MAL-UNION FOLLOWING LONG BONE FRACTURE**
Dunlop S¹, Ekegren CL², Edwards ER³, de Steiger R⁴, Page R⁵, Gabbe BJ^{2,1}, Zimmer Biomet, Belrose, Australia, ²Monash University, Melbourne, Australia, ³The Alfred Hospital, Prahran, Australia, ⁴Epworth Hospital, Richmond, Australia, ⁵University Hospital Geelong, Geelong, Australia
- PMS9 S3 MODELING THE COST-EFFECTIVENESS OF STATIN THERAPY IN RHEUMATOID ARTHRITIS A MARKOV-CYCLE EVALUATION FROM THE NATIONAL DATA BANK FOR RHEUMATIC DISEASES**
Almasri D¹, Lai L², Michaud K^{3,1}, King Abdulaziz University, Jeddah, Saudi Arabia, ²Nova Southeastern University, Davie, FL, USA, ³University of Nebraska Medical Center, Omaha, NE, USA
- PMS10 S4 EVALUATE THE COST-EFFECTIVE THRESHOLD OF OSTEOPOROSIS TREATMENT ON ELDERLY WOMEN IN CHINA USING DISCRETE EVENT SIMULATION MODEL**
Ni W, Jiang Y, University of Southern California, Los Angeles, CA, USA
- PMS11 S5 COST-EFFECTIVENESS OF BISPHOSPHONATES FOR PRIMARY AND SECONDARY PREVENTION OF HIP-RELATED FRACTURE WITH GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MALAYSIA**
Mohd Tahir NA¹, Thomas P², Makmor Bakry M³, Mohamed Said MS⁴, Li SC^{1,1}, University of Newcastle, Callaghan, NSW, Australia, ²Taylor's University, Selangor, Malaysia, ³Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ⁴Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
- PMS12 S6 ECONOMIC EVALUATION OF DIACEREIN, DICLOFENAC AND GLUCOSAMINE FOR OSTEOARTHRITIS IN CHINA**
Li H¹, Ma A¹, Tian L¹, Fu Y¹, Liu GG^{2,1}, China Pharmaceutical University, Nanjing, China, ²Peking University, Beijing, China

MUSCULAR-SKELETAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PMS13 S7 TREATMENT SATISFACTION OF OSTEOPOROSIS MEDICATION IN POSTMENOPAUSAL WOMEN OF KOREA; RESULTS FROM THE STUDY OF OSTEOPOROSIS MEDICATION ADHERENCE AND SATISFACTION IN POSTMENOPAUSAL WOMEN**
Byun D¹, Moon S², Kim T³, Kim Y⁴, Seo B⁴, Min Y^{5,1}, Soonchunhyang University Hospital, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, South Korea, ³College of Medicine, Korea University, Seoul, South Korea, ⁴Pfizer Pharmaceuticals Korea Ltd., Seoul, South Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- PMS14 S8 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AT UTTARADIT HOSPITAL,**

THAILAND

Pongmesa T¹, Munchey R²,¹Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand, ²Nampad Hospital, Uttaradit, Thailand

PMS15 S9 PSYCHOLOGICAL DISTRESS IN CHINESE PATIENTS WITH RHEUMATOID ARTHRITIS AND PSYCHOMETRIC VALIDATION OF CHINESE HOSPITAL ANXIETY AND DEPRESSION SCALE

Hu H¹, Luan L¹, Yang KQ², Li SC¹,¹University of Newcastle, Callaghan, NSW, Australia, ²Taizhou No.4 Renmin Hospital, Jiangsu, China

PMS16 S10 PRODUCTIVITY LOSS OF RHEUMATOID ARTHRITIS PATIENTS BY THEIR LEVEL OF DISEASE ACTIVITY SCORE

Bae S¹, Koh H², Kim Y²,¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Pfizer Pharmaceuticals Korea Limited, Seoul, South Korea

MUSCULAR-SKELETAL DISORDERS - Health Care Use & Policy Studies

PMS18 T1 TREATMENT GAP OF POST OSTEOPOROTIC FRACTURES IN TAIWAN: A NATIONWIDE COHORT STUDY, 2008-2013

Wang C¹, Fu S², Huang C², Hung C², Huang S¹, Lin C³, Hsiao F³,¹School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, ²Department of orthopedics, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County, Taiwan, Yunlin, Taiwan, ³National Taiwan University, Taipei, Taiwan

PMS19 T2 PERSISTENCE WITH BIOLOGIC AGENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN JAPAN

Mahlich JC¹, Sruamsiri R²,¹Janssen KK, Tokyo, Japan, ²Janssen Pharmaceutical KK, Tokyo, Japan

PMS20 T3 TREATMENT PATTERNS OF RHEUMATOID ARTHRITIS IN JAPANESE HOSPITALS AND PREDICTORS OF INITIATION BIOLOGIC AGENTS

Mahlich JC¹, Sruamsiri R²,¹Janssen KK, Tokyo, Japan, ²Janssen Pharmaceutical KK, Tokyo, Japan

PMS21 T4 MAPPING THE PRESCRIPTION TREND FOR RHEUMATOID ARTHRITIS IN MUMBAI, INDIA

Kulkarni AS, Kelkar RS, Majumdar AS, Bombay College of Pharmacy, Mumbai, India